Medifocus Inc. (TSXV-MFS)

About Medifocus Inc.

Medifocus, Inc. (TSXV-MFS, OTC-MDFZF) is in the business of development and commercialization of minimally invasive, focused-heat tumor targeted cancer and benign tumor treatment devices and systems. It plans to raise the standards of breast cancer care and treatment by using focused microwave heating to enhance neoadjuvant chemotherapy to provide better tumor shrinkage and control, leading to improved surgical outcomes and ultimately breast preservation. Medifocus is current running a Phase III pivotal study to commercialize its Breast Cancer Treatment Device. Medifocus recently announced it has purchased the Prolieve Thermodilatation® System Assets from Boston Scientific. The FDA approved device Prolieve® is for the treatment of Benign Prostatic Hyperplasia (BPH). BPH is the enlargement of the male prostate gland which affects over 50 percent of men over the age of 50. Medifocus is currently deriving revenue from the sales of the Prolieve® device.

Medifocus' patented adaptive phased array (APA) microwave focusing technology platform licensed from the Massachusetts Institute of Technology (MIT) provides the design of the Company's unique focused heat treatment systems with the capability to direct precision-focused microwave energy at targeted tumor to induce hyperthermia to shrink or eradicate tumors without undue harm to surrounding tissue.

The Company's goal is to improve outcomes and standards of care in cancer treatment. Its first indication, locally advanced breast cancer (LABC), involves large tumors that are generally treated first with neo-adjuvant chemotherapy to induce tumor shrinkage and then followed by either mastectomy (complete removal of the breast) or lumpectomy (breast conservation surgery), depending on the final size of the tumor. Medifocus' focused-heat treatment can significantly improve the efficacy of neo-adjuvant chemotherapy in shrinking large breast cancer tumors, significantly improving the chance of breast conservation, and decreasing the need for radical breast surgery. Focused microwaves can be used to shrink breast tumors up to 8 cm in diameter, vastly improving the chance of breast conservation for these patients who under normal circumstances will have no option but to undergo mastectomy.

Medifocus' patented Prolieve® device utilizes a patented intra-cavitary catheter to deliver a combination of microwave heating and balloon dilatation of the prostatic urethra which leads to the relief of BPH symptoms. Treatment with Prolieve® is a minimally invasive non-surgical in-office procedure which offers patients clinically documented immediate reduction of BPH symptom scores. Prolieve is the only microwave device to be randomized to drug therapy during its pivotal trial.

The Company recently completed a private placement of over $5.0 Million to purchase the Prolieve® assets and to expand the current Prolieve® business opportunity.  

Medifocus, Inc. (TSXV-MFS)
© 2007 - 2023 Medifocus. All Rights Reserved. Legal Disclaimers